Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DNAP001679

Drug Information
NameCrizotinib
Trade NameXalkori
CompanyPfizer New York, NY
IndicationALK-positive advanced or metastatic NSCLC
[ICD9: 162   ICD10: C33, C34]
Approved    
First-line ALK-positive NSCLC, second-line ALK-positive NSCLC (see also solid tumors)
[ICD9: 140-199, 162, 210-229   ICD10: C00-C75, C33, C34, C7A, C7B, D10-D36, D3A]
Phase III    
NSCLC (combination therapy)
[ICD9: 162   ICD10: C33, C34]
Phase I/II    
Solid Tumors
[ICD9: 140-199, 210-229   ICD10: C00-C75, C7A, C7B, D10-D36, D3A]
Phase I    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-2
7-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-
7H2,1H3,(H2,25,27)/t12-/m1/s1
InChIKeyKTEIFNKAUNYNJU-GFCCVEGCSA-N
Canonical SMILESCC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N    
Isomeric SMILESC[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
CAS NumberCAS 877399-52-5
FormulaC21H22Cl2FN5O
PubChem Compound IDCID 11626560.
SuperDrug ATC IDL01XE16
TargetALK
HGFR
ROS1



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543